Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
复制标题
DOI：
10.1007/s00535-014-0936-0
复制
发表时间：
2014-12
影响因子：
6.3
通讯作者：
Kudo, Masatoshi
中科院分区：
文献类型：
--
作者：
Arizumi, Tadaaki;Ueshima, Kazuomi;Takeda, Haruhiko;Osaki, Yukio;Takita, Masahiro;Inoue, Tatsuo;Kitai, Satoshi;Yada, Norihisa;Hagiwara, Satoru;Minami, Yasunori;Sakurai, Toshiharu;Nishida, Naoshi;Kudo, Masatoshi
关键词：
为了验证在肝癌（RECICL）中使用反应评价标准的假设，一个改进的评价系统旨在解决实体瘤1.1反应评价标准（RECIST1.1）和改进的RECIST （mRECIST）的局限性，提供了更准确的评估肝细胞癌（HCC）患者对索拉非尼（一种分子靶向药物）治疗的反应，以总生存期（OS）评估。使用recst1.1、mRECIST和RECICL对156例接受索拉非尼治疗超过1个月的晚期HCC患者的治疗反应进行了评估。在分类为进展性疾病（PD）、稳定性疾病（SD）或客观反应后，使用Kaplan-Meier方法检查OS与分类之间的关系，以形成生存曲线。141例经recst1.1分级为PD或SD，但经mRECIST和RECICL分级为客观反应的病例，进一步分析OS与分级的相关性。仅发现使用RECICL分类与OS显著相关（p = 0.0033）。在经recst1.1分类为SD或PD的患者中，经RECICL而非mRECIST重新分类的患者与OS显著相关，可以精确预测预后（p = 0.0066）。只有使用RECICL才能鉴别出索拉非尼治疗后预后改善的HCC患者亚组。因此，RECICL应被认为是评估治疗反应的一种较好的系统。本文的在线版本（doi:10.1007/s00535-014-0936-0）包含补充材料，仅供授权用户使用。
To test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS). The therapeutic response of 156 patients with advanced HCC who had been treated with sorafenib therapy for more than 1 month was evaluated using the RECIST1.1, mRECIST, and RECICL. After categorization as showing progressive disease (PD), stable disease (SD), or objective response, the association between OS and categorization was examined using the Kaplan–Meier method to develop survival curves. The 141 cases categorized as PD or SD by the RECIST1.1, but objective response by the mRECIST and RECICL, were further analyzed for determination of the association between OS and categorization. Only categorization using the RECICL was found to be significantly correlated with OS (p = 0.0033). Among the patients categorized as SD or PD by the RECIST1.1, reclassification by the RECICL but not the mRECIST was found to be significantly associated with OS and allowed for precise prediction of prognosis (p = 0.0066). Only the use of the RECICL allowed for identification of a subgroup of HCC patients treated with sorafenib with improved prognosis. The RECICL should, therefore, be considered a superior system for assessment of therapeutic response. The online version of this article (doi:10.1007/s00535-014-0936-0) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
13.5
作者：
Llovet, Josep M.;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen
影响因子：
6.2
作者：
Ebied, OM;Federle, MP;Zajko, A
通讯作者：
Zajko, A
影响因子：
5.7
作者：
Kano, Mitsunobu R.;Komuta, Yukari;Miyazono, Kohei
通讯作者：
Miyazono, Kohei